secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0000950170-25-047196
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q4/FY2024 results: cash $164M, R&D spend up, protocol deviation in SSc trial
--------------------------------------------------------------------------------

- Cash and equivalents $164M as of Dec 31, 2024, providing runway into first half of 2026.
- R&D expenses for FY2024 were $97.2M, up from $55.4M in FY2023.
- Enrolled 33 patients across RESET program as of Mar 14, 2025; FDA meeting on myositis trial designs on track for 1H25.
- Protocol deviation in RESET-SSc: patient infused with fever developed grade 3 ICANS; IDMC recommended trial continue.
- Expanded CDMO agreement with Lonza for rese-cel clinical product supply starting 2H25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000095017025047196/0000950170-25-047196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000095017025047196/caba-20250331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-047196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer